Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BMS-911543 |
Synonyms | |
Therapy Description |
BMS-911543 is a selective ATP-competitive inhibitor of JAK2, which may decrease tumor cell proliferation (PMID: 22015772, PMID: 26288683, PMID: 30388009). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-911543 | BMS 911543|BMS911543 | JAK2 Inhibitor - ATP competitive 15 | BMS-911543 is a selective ATP-competitive inhibitor of JAK2, which may decrease tumor cell proliferation (PMID: 22015772, PMID: 26288683, PMID: 30388009). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 V617F | myeloproliferative neoplasm | sensitive | BMS-911543 | Preclinical - Cell culture | Actionable | In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring JAK2 V617F in culture (PMID: 22015772). | 22015772 |
JAK2 V617F | essential thrombocythemia | sensitive | BMS-911543 | Preclinical - Cell culture | Actionable | In a preclinical study, BMS-911543 inhibited proliferation and induced apoptosis in an essential thrombocythemia cell line harboring JAK2 V617F in culture (PMID: 22015772). | 22015772 |
JAK2 V617F | hematologic cancer | sensitive | BMS-911543 | Preclinical - Cell culture | Actionable | In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing JAK2 V617F in culture (PMID: 22015772). | 22015772 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|